Distributor shortlist with reasons
A ranked shortlist per market, with registration status, hospital coverage and reference checks noted for each name.
Your export department
in Central & Eastern Europe
TYMES helps global MedTech manufacturers enter Central & Eastern Europe without building a local representation. We identify and vet distributors, coordinate regulatory requirements, manage commercial negotiations and support the transaction through delivery and after-sales.
The friction
Sound familiar?
Cold outreach from LinkedIn is full of soft promises. These are the concrete frictions manufacturers hit when entering CEE without a local office.
We do not know whom to trust with our brand and pricing
We have no trusted local partner to manage the market
Counterparties look fine on paper until diligence starts
Registration paths differ by country and nobody owns the file
After-sales disappears once the container lands
No single partner owns the entire U.S.–CEE process
The deliverables
What you receive
A written regulatory route
Per country: EU MDR or national registration, dossier owner, expected timeline and who pays for what.
One commercial counterparty
You invoice an entity based in the USA under United States law. We help reduce and manage the currency, credit and collection exposure downstream.
Market reporting, in writing
Volumes, tender calendar, competitor pricing movement and what changed in regulation — cadence agreed per engagement, always in English and in writing.
FAQ
Questions manufacturers ask
Commission agency is our default: you invoice the buyer directly. Under a buy-sell engagement, where available, we purchase on our own account instead.
Sourcing and diligence typically take three to four weeks. Registration is regulator-dependent and often three to eight weeks. We publish indicative ranges and confirm per engagement.
Yes, when written into the agreement. Pricing floors and territory limits are enforceable terms, or we decline the deal.
Due diligence, written counterparties and document trails are part of the engagement. We do not offer grey-import routes or undocumented payments.
When scoped into the deal, yes: instruments are named in the term sheet.
Sample logistics can be coordinated as part of sourcing and introduction. Criteria for acceptance are written before samples move.
TYMES was founded in 2025 in the United States after 10+ years of medical distribution work in Ukraine. We know how tenders, customs and hospital acceptance actually run.
Next step
Send one page. We will send back a route
Device category, target markets, volume and timeline. That is enough for a first written answer.